查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1946432

莫努匹拉韦市场 - 全球产业规模、份额、趋势、机会及预测（按应用、分销管道、地区和竞争格局划分，2021-2031年）

Molnupiravir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球莫努匹拉韦市场预计将从 2025 年的 10.1 亿美元成长到 2031 年的 14.4 亿美元，复合年增长率为 6.09%。

莫努匹拉韦是一种口服核糖核苷类似物，它透过诱导病毒基因组错误来抑制SARS-CoV-2的复製。其市场需求主要源自于其方便非住院患者服用，以及在治疗无法取得其他药物的高危险群方面的重要作用。製药业对疫情因应的持续投入也支撑了这一商业性趋势。正如国际药品製造商协会联合会（IFPMA）所指出的，到2024年，私部门将占新冠肺炎药物研发管线创投的75%，凸显了各方对开发可及抗病毒药物的持续承诺。

市场概览
预测期 2027-2031
市场规模：2025年 10.1亿美元
市场规模：2031年 14.4亿美元
复合年增长率：2026-2031年 6.09%
成长最快的细分市场 网路药房
最大的市场 北美洲

然而，市场扩张仍面临许多障碍。一个关键因素是，由于其他疗效较佳的竞争疗法占据主导地位，医疗机构对莫努匹拉韦的接受度下降。全球检测率和就医意愿的下降进一步加剧了这种竞争劣势，限制了合格的患者数量。此外，监管机构持续对其安全性进行审查，也加剧了这些问题，限制了该药物在后疫情时代更广泛应用的商业环境。

市场驱动因素

政府采购和战略储备的扩大仍然是全球莫努匹拉韦市场的主要驱动力，因为各国卫生部门都将长期药品安全放在首位。儘管紧急采购有所发展，但集中采购仍是主要的收入来源，各国维持储备以应对未来的病毒爆发。财务数据也印证了这种对国家合约的依赖。默克在其2024年2月发布的「2023年第四季及全年财务业绩」中报告称，LaGebrio的年销售额达到14亿美元。这表明，儘管商业环境发生变化，但政府订单仍然推动了可观的销售量。此类储备确保了在局部疫情爆发时即时供应抗病毒药物，并有效稳定市场，使其免受零售需求波动的影响。

此外，随着人们越来越重视减轻医疗负担和减少住院人数，口服抗病毒药物作为预防高风险族群重症的关键干预措施，正获得越来越多的市场份额。病毒变异株的持续传播加剧了医疗基础设施的压力，因此，必须采取有效的早期治疗来预防加护病房（ICU）的住院。根据世界卫生组织（世卫组织）2024年12月发布的《COVID-19流行病学最新情况》，年初加护病房入住率已超过每千名住院患者191例，凸显了患者预后的不确定性。持续的感染率进一步加剧了这项需求。世卫组织报告称，2024年全球仅在四週内就新增了超过20万例病例，证实了持续的流行病学负担，也凸显了莫努匹拉韦的效用。

市场挑战

全球莫努匹拉韦市场面临的主要障碍是全球检测率和就医意愿的显着下降。莫努匹拉韦只有在症状出现后五天内服用才有效，因此及时诊断是处方的先决条件。随着政府监测计画的缩减和民众对症状的警觉性降低，符合抗病毒治疗条件的确诊病例数大幅下降。诊断率的下降直接导致潜在市场规模（TAM）缩小，因为未确诊的患者无论药物供应和临床疗效如何，都无法获得该药物。

近期行业数据也印证了诊断活动下降的趋势。美国临床实验室协会报告称，到2024年，新冠病毒实验室检测量将年减57%。检测量的急剧下降对市场成长构成根本性障碍，因为莫努匹拉韦的商业性可行性与阳性病例检出率密不可分。如果没有稳定的确诊患者来源，口服抗病毒药物的需求将面临严重的自然增长瓶颈，从而进一步加剧来自其他治疗方案的竞争压力。

市场趋势

联合抗病毒疗法的出现正成为市场上的显着趋势。这种方法旨在透过多种联合治疗来提高疗效并降低病毒抗药性。将莫努匹拉韦与现有抗病毒药物联合使用正日益受到重视，尤其是在病毒载量高、存在多种突变的复杂病例中，以产生超越单药治疗的协同效应。这一科学转变得到了近期临床前数据的支持。发表于2024年11月《抗病毒研究》（Antiviral Research）杂誌的一篇题为“瑞德西韦（GS-441524）、莫努匹拉韦和Ribavirin三联联合治疗高效抑制冠状病毒复製”的论文报告称，三联药物通讯协定完全清除了仓鼠肺部可检测到的感染性病毒突破性方案，这可能会取得未来治疗突破性通讯协定，这可能会取得成功。

同时，市场正转向预防性和高风险应用，重点在于药物能发挥最大价值的特定患者亚群。随着群体免疫的广泛普及降低了大规模治疗的需求，临床定位越来越倾向于未接种疫苗且面临最高死亡风险的弱势群体。这种精细的处方策略旨在最大限度地提高药物在这些特定族群中预防严重后果的疗效。临床数据支持这种标靶治疗策略。根据发表于2024年6月《微生物学、免疫学和感染杂誌》的最新Meta分析“莫努匹拉韦治疗COVID-19门诊病人”，该疗法在所有研究人群中将全因死亡风险降低了0.28倍。这支持了在弱势患者群体中继续使用该疗法，儘管在已接种疫苗的人群中未观察到显着获益。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球莫努匹拉韦市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依应用（流感、伊波拉、新冠肺炎、其他）
    • 按分销管道（医院药房、零售药房、网路药房）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美莫努匹拉韦市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲莫努匹拉韦市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区莫努匹拉韦市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲莫努匹拉韦市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章 南美洲莫努匹拉韦市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

第十三章 全球莫努匹拉韦市场：SWOT分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Merck & Co., Inc.
  • Ridgeback Biotherapeutics
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Hetero Drugs Limited
  • Torrent Pharmaceuticals Ltd.
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Beximco Pharma Limited
  • Natco Pharma Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 10604

The Global Molnupiravir Market is projected to expand from USD 1.01 Billion in 2025 to USD 1.44 Billion by 2031, registering a CAGR of 6.09%. As an orally administered ribonucleoside analog, Molnupiravir functions by inducing errors in the viral genetic code to inhibit SARS-CoV-2 replication. Market demand is largely sustained by its convenient administration for non-hospitalized patients and its critical role in treating high-risk demographics unable to use alternative agents. This commercial trajectory is supported by ongoing industry commitment to pandemic preparedness; as noted by the International Federation of Pharmaceutical Manufacturers & Associations, the private sector contributed 75% of the at-risk investment in the COVID-19 therapeutics pipeline in 2024, highlighting a continued dedication to accessible antiviral development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.01 Billion
Market Size 2031USD 1.44 Billion
CAGR 2026-20316.09%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

However, market expansion faces significant hurdles, primarily due to the dominance of competing therapies that offer superior clinical efficacy, thereby reducing Molnupiravir's selection by healthcare providers. This competitive disadvantage is compounded by a global reduction in testing rates and treatment-seeking behaviors, which limits the volume of eligible patients. Furthermore, these issues are exacerbated by persistent regulatory scrutiny regarding safety profiles, creating a constrained commercial environment for broader adoption in the post-pandemic era.

Market Driver

The expansion of government procurement and strategic stockpiling remains a fundamental driver for the Global Molnupiravir Market as national health agencies emphasize long-term pharmaceutical security. Although emergency purchasing has evolved, centralized buying continues to be the primary revenue source, with nations maintaining reserves to buffer against future viral surges. This reliance on state-level contracts is confirmed by financial data; Merck & Co., Inc. reported full-year Lagevrio sales of $1.4 billion in their 'Fourth Quarter and Full Year 2023 Financial Results' released in February 2024, demonstrating substantial volume from government orders despite broader commercial shifts. Such stockpiling ensures immediate antiviral access during localized outbreaks, effectively stabilizing the market against retail demand volatility.

Additionally, the market is propelled by an increased focus on alleviating healthcare burdens and reducing hospitalizations, with oral antivirals serving as a vital intervention for preventing severe disease in at-risk populations. This priority is reinforced by the continued circulation of viral variants that strain medical infrastructure, necessitating effective early-stage treatments to prevent ICU admissions. According to the World Health Organization's 'COVID-19 Epidemiological Update' from December 2024, ICU admissions rose to over 191 per 1,000 hospitalizations early in the year, highlighting the unpredictable nature of patient outcomes. This necessity is further amplified by sustained transmission rates, with the World Health Organization reporting over 200,000 new cases globally in a single four-week period in 2024, confirming the ongoing epidemiological burden that underscores Molnupiravir's utility.

Market Challenge

A primary obstacle hindering the Global Molnupiravir Market is the substantial global decrease in testing rates and treatment-seeking behavior. Because Molnupiravir requires administration within five days of symptom onset to be effective, timely diagnosis is a prerequisite for its prescription. With governments scaling back surveillance programs and the public showing reduced vigilance toward symptoms, the pool of confirmed cases eligible for antiviral therapy has contracted significantly. This drop in diagnostic volume directly reduces the total addressable market, as unidentified patients remain unable to access the medication regardless of its availability or clinical benefits.

Recent industry data substantiates this downward trend in diagnostic activity. The 'American Clinical Laboratory Association' reported in '2024' that 'COVID-19 clinical lab volumes declined by 57% year-over-year.' This sharp reduction in testing creates a fundamental barrier to market growth, as the commercial viability of Molnupiravir is inextricably tied to the rate of positive case identification. Without a consistent stream of diagnosed patients, the demand for oral antivirals faces a severe natural ceiling, which further intensifies the competitive pressures posed by alternative therapeutic options.

Market Trends

The emergence of combination antiviral therapies is becoming a defining market trend, aiming to improve therapeutic potency and mitigate viral resistance through multi-agent regimens. Research efforts are intensifying around the co-administration of Molnupiravir with other established antivirals to generate synergistic effects that exceed the outcomes of monotherapy, particularly for complex cases involving high viral loads or mutations. This scientific shift is supported by recent preclinical evidence; an article in Antiviral Research from November 2024, titled 'The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication,' reported that a triple-drug protocol completely eliminated detectable infectious virus in hamster lungs, signaling a potential breakthrough for future treatment protocols.

Concurrently, the market is pivoting toward prophylactic and high-risk applications, focusing utilization on specific patient subgroups where the drug offers the highest value. As widespread population immunity reduces the need for mass treatment, clinical positioning is increasingly targeting unvaccinated or vulnerable individuals who face the highest mortality risks. This refined prescribing strategy aims to maximize efficacy regarding severe outcomes within these specific niches. Clinical data supports this targeted approach; according to the 'Journal of Microbiology, Immunology and Infection' in June 2024, an updated meta-analysis titled 'Molnupiravir for the treatment of COVID-19 outpatients' found that the therapy reduced the risk of all-cause mortality with a risk ratio of 0.28 in the overall population, validating its continued use for vulnerable patients despite a lack of significant benefit in immunized groups.

Key Market Players

  • Merck & Co., Inc.
  • Ridgeback Biotherapeutics
  • Cipla Limited
  • Sun Pharmaceutical Industries Ltd.
  • Hetero Drugs Limited
  • Torrent Pharmaceuticals Ltd.
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories Ltd.
  • Beximco Pharma Limited
  • Natco Pharma Ltd.

Report Scope

In this report, the Global Molnupiravir Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Molnupiravir Market, By Application

  • Influenza
  • Ebola
  • COVID-19
  • Others

Molnupiravir Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Molnupiravir Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Molnupiravir Market.

Available Customizations:

Global Molnupiravir Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Molnupiravir Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Influenza, Ebola, COVID-19, Others)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Molnupiravir Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Molnupiravir Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Molnupiravir Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Molnupiravir Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Distribution Channel

7. Europe Molnupiravir Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Molnupiravir Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Molnupiravir Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Molnupiravir Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Molnupiravir Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Molnupiravir Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Molnupiravir Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Molnupiravir Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Molnupiravir Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Molnupiravir Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Molnupiravir Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Molnupiravir Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Molnupiravir Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Molnupiravir Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Molnupiravir Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Molnupiravir Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Distribution Channel

10. South America Molnupiravir Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Molnupiravir Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Molnupiravir Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Molnupiravir Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Molnupiravir Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck & Co., Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Ridgeback Biotherapeutics
  • 15.3. Cipla Limited
  • 15.4. Sun Pharmaceutical Industries Ltd.
  • 15.5. Hetero Drugs Limited
  • 15.6. Torrent Pharmaceuticals Ltd.
  • 15.7. Aurobindo Pharma Limited
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Beximco Pharma Limited
  • 15.10. Natco Pharma Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer